Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Therapeutic Neuroprotection by an Engineered Neurotrophin that Selectively Activates Tropomyosin Receptor Kinase (Trk) Family Neurotrophin Receptors but Not the p75 Neurotrophin Receptor

Fouad Brahimi, Alba Galan, Sairey Siegel, Stephanie Szobota, Marinko V. Sarunic, Alan C. Foster and H. Uri Saragovi
Molecular Pharmacology November 2021, 100 (5) 491-501; DOI: https://doi.org/10.1124/molpharm.121.000301
Fouad Brahimi
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alba Galan
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sairey Siegel
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Szobota
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marinko V. Sarunic
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan C. Foster
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Uri Saragovi
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 100 no. 5 491-501
DOI 
https://doi.org/10.1124/molpharm.121.000301
PubMed 
34470776

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received April 14, 2021
  • Accepted August 12, 2021
  • Published online October 22, 2021.

Article Versions

  • Earlier version (August 31, 2021 - 19:49).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Fouad Brahimi,
  2. Alba Galan,
  3. Sairey Siegel,
  4. Stephanie Szobota,
  5. Marinko V. Sarunic,
  6. Alan C. Foster, and
  7. H. Uri Saragovi
  1. Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
  1. Address correspondence to:
    H. Uri Saragovi, Lady Davis Institute-Jewish General Hospital, 3755 Cote Ste-Catherine Road, Room E-535, Montreal H3T 1E2 Canada. E-mail: uri.saragovi{at}mcgill.ca
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2021 to January 2023

AbstractFullPdf
Aug 2021801
Sep 2021268096
Oct 20212221258
Nov 20211641520
Dec 202182714
Jan 202265712
Feb 202264109
Mar 20225289
Apr 20226756
May 20223786
Jun 20227447
Jul 20224443
Aug 20226558
Sep 202263810
Oct 202231169
Nov 202272710
Dec 20223167
Jan 20236168

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 100 (5)
Molecular Pharmacology
Vol. 100, Issue 5
1 Nov 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic Neuroprotection by an Engineered Neurotrophin that Selectively Activates Tropomyosin Receptor Kinase (Trk) Family Neurotrophin Receptors but Not the p75 Neurotrophin Receptor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

In Vivo Efficacy of a Pan-Trk Agonist with Low p75 Affinity

Fouad Brahimi, Alba Galan, Sairey Siegel, Stephanie Szobota, Marinko V. Sarunic, Alan C. Foster and H. Uri Saragovi
Molecular Pharmacology November 1, 2021, 100 (5) 491-501; DOI: https://doi.org/10.1124/molpharm.121.000301

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

In Vivo Efficacy of a Pan-Trk Agonist with Low p75 Affinity

Fouad Brahimi, Alba Galan, Sairey Siegel, Stephanie Szobota, Marinko V. Sarunic, Alan C. Foster and H. Uri Saragovi
Molecular Pharmacology November 1, 2021, 100 (5) 491-501; DOI: https://doi.org/10.1124/molpharm.121.000301
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics